TRIMAINE BRINKLEY: Open Payments
NPI 1871721464 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$743 in 35 payments from 9 companies in 2025. Trend: 2023 $435 · 2024 $552 · 2025 $743
Food & beverage: $743
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 8 | $191 |
| E.R. Squibb & Sons, L.L.C. | 12 | $184 |
| Janssen Pharmaceuticals, Inc | 4 | $138 |
| ABBVIE INC. | 3 | $61 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: COBENFY, ARISTADA, INVEGA SUSTENNA, VRAYLAR, INGREZZA, LYBALVI, REXULTI, TRINTELLIX.
Industry payments across SC — which companies pay providers there.
